Biostar Pharmaceuticals expects 2010 revenues of about $70 million and net income of $17 million, excluding non-cash charges. The company is on track to report 2009 revenues of around $52 million, which means the 2010 guidance represents an increase of 35%. About 70% of Biostar’s revenues are generated by Xin Aoxing Oleanolic Acid Capsules, an over-the-counter TCM treatment for hepatitis B. More details...

Stock Symbol: (OTCBB: BSPM)